Cautious uptake of Merck's Winrevair gives opportunity to rivals, Oppenheimer says

Keros Therapeutics

14/11/2024 12:49

** Brokerage Oppenheimer says there is an opportunity for
competition given a cautious uptake of Merck's  MRK.N  therapy,
Winrevair, for a rare lung condition
    ** Early trends of Merck's therapy indicate the sickest
patients being prioritized - brokerage
    ** U.S. FDA approved the therapy for treating pulmonary
arterial hypertension in March this year
    ** As of Sept. 30, FDA's adverse event reporting system
lists 254 cases, with 103 serious, including 8 reported deaths,
believed to be related to MRK's therapy
    ** Doctors exercise heightened caution when recommending it
to patients with a history of bleeding risks
    ** As the safety profile continues to emerge, there is an
opportunity for potentially safer treatments that could be used
in earlier lines, says brokerage
    ** There is potential for Keros Therapeutics'  KROS.O 
cibotercept for higher dosing compared to Winrevair, says
Oppenheimer
    ** Gossamer Bio's  GOSS.O  seralutinib stands out with a
clean long-term safety and efficacy profile

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))